Original Articles
Published October 31, 2018
Article Tools
Article Level Metrics
Share this article
facebook twitter linkedin


Pseudomonas Aeruginosa (P. aeruginosa)
Efflux Pump
Phenylalanine-arginine Beta-naphthylamide (PAβN)

How to Cite

Abbasi, F., Yusefi, S., & Afshar Yavar, S. (2018). Minimum Inhibitory Concentration of Ciprofloxacin against Pseudomonas Aeruginosa in the Presence of the Efflux Inhibitor Phenylalanine-arginine Beta-naphthylamide. Internal Medicine and Medical Investigation Journal, 3(4). https://doi.org/10.24200/imminv.v2i4.128

Minimum Inhibitory Concentration of Ciprofloxacin against Pseudomonas Aeruginosa in the Presence of the Efflux Inhibitor Phenylalanine-arginine Beta-naphthylamide

Fatemeh Abbasi
Faulty of Medicine, Urmia Medical Sciences University, Urmia, Iran.
Saber Yusefi
Department of Microbiology and Virology, Faulty of Medicine, Urmia Medical Sciences University, Urmia, Iran.
Shohreh Afshar Yavar
Department of Laboratory Sciences, Faculty of Paramedical Sciences Urmia Medical Sciences University, Urmia, Iran.

Introduction: Pseudomonas aeruginosa is a gram-negative, opportunistic pathogen causing infections in patients staying in the hospital and is resistant to multiple drugs. This study investigated the resistance to ciprofloxacin by the efflux system of Pseudomonas aeruginosa.

Materials and Methods: For this purpose, the inhibitor of the efflux system phenylalanine-arginine beta-naphthylamide was used. In this study, 135 isolates of Pseudomonas aeruginosa were collected from the hospitalized patients of Imam Khomeini Hospital and outpatient clinics in Urmia during a ten-month period from June 2015 to March 2016. These isolates were re-identified by standard microbiological and biochemical methods. Finally, 51 isolates were selected for antibiotic susceptibility testing.

Results: According to the antibiogram test, the Pseudomonas aeruginosa isolates exhibited highest resistance against ciprofloxacin (90.2%), tobramycin (88.2%), and gentamycin (86.3%) and the highest sensitivity towards colistin (76.4%), and imipenem (72.5%). The 51 isolates, which were selected for the minimum inhibitory concentration test, had multi-drug resistance regulators.

Conclusion: The discovery and development of the efflux system inhibitors is an important strategy to deal with bacterial infections.



Dulon S, Leduc D, Cottrell GS, D’alayer J, Hansen KK, Bunnett NW, et al. Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. American journal of respiratory cell and molecular biology. 2005; 32(5):411-9.

Aghamollaei H, Moghaddam MM, Kooshki H, Heiat M, Mirnejad R, Barzi NS. Detection of Pseudomonas aeruginosa by a triplex polymerase chain reaction assay based on lasI/R and gyrB genes. Journal of infection and public health. 2015; 8(4):314-22.

Deschaght P, De Baets F, Vaneechoutte M. PCR and the detection of Pseudomonas aeruginosa in respiratory samples of CF patients. A literature review. Journal of Cystic Fibrosis. 2011; 10(5):293-7.

Pearson JP, Feldman M, Iglewski BH, Prince A. Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection. Infection and immunity. 2000; 68(7):4331-4.

Mima T, Sekiya H, Mizushima T, Kuroda T, Tsuchiya T. Gene cloning and properties of the RND-type multidrug efflux pumps MexPQ-OpmE and MexMN-OprM from Pseudomonas aeruginosa. Microbiology and immunology. 2005;49(11):999-1002.

Pragasam A, Vijayakumar S, Bakthavatchalam Y, Kapil A, Das B, Ray P, et al. Molecular characterisation of antimicrobial resistance in Pseudomonas aeruginosa and Acinetobacter baumannii during 2014 and 2015 collected across India. Indian journal of medical microbiology. 2016; 34(4):433.

Lambert P. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. Journal of the royal society of medicine. 2002; 95(Suppl 41):22.

Pagès J-M, Masi M, Barbe J. Inhibitors of efflux pumps in Gram-negative bacteria. Trends in molecular medicine. 2005; 11(8):382-9.

Rezaei F, Saderi H, Boroumandi S, Faghihzadeh S. Relation between Resistance to Antipseudomonal β-Lactams and ampC and mexC Genes of Pseudomonas aeruginosa. Iranian journal of pathology. 2016; 11(1):47.

Strateva T, Yordanov D. Pseudomonas aeruginosa–a phenomenon of bacterial resistance. Journal of medical microbiology. 2009; 58(9):1133-48.

Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. Journal of molecular microbiology and biotechnology. 2001; 3(2):255-64.

Jabalameli F, Mirsalehian A, Khoramian B, Aligholi M, Khoramrooz SS, Asadollahi P, et al. Evaluation of biofilm production and characterization of genes encoding type III secretion system among Pseudomonas aeruginosa isolated from burn patients. Burns. 2012; 38(8):1192-7.

Soto SM. Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence. 2013; 4(3):223-9.

Zhang L, Mah T-F. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. Journal of bacteriology. 2008; 190(13):4447-52.

Lamers RP, Cavallari JF, Burrows LL. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria. PLoS One. 2013; 8(3):e60666.

Rana T, Kaur N, Farooq U, Singh S, Khan A. Efflux As An Arising Cause Of Drug Resistance In Punjab (India). IJBPAS. 2015; 4(9): 5967-5979.

Wayne P. Clinical and Laboratory Standards Institute (CLSI) performance standards for antimicrobial disk diffusion susceptibility tests 19th ed. approved standard. CLSI document M100-S19. 2009; 29.

P Tegos G, Haynes M, Jacob Strouse J, Md T Khan M, G Bologa C, I Oprea T, et al. Microbial efflux pump inhibition: tactics and strategies. Current pharmaceutical design. 2011; 17(13):1291-302.

Sonnet P, Izard D, Mullié C. Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-β-naphthylamide. International journal of antimicrobial agents. 2012; 39(1):77-80.

Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clinical Microbiology and Infection. 2007; 13(6):560-78.

Adabi M, Talebi-Taher M, Arbabi L, Afshar M, Fathizadeh S, Minaeian S, et al. Spread of efflux pump overexpressing-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa by using an efflux pump inhibitor. Infection & chemotherapy. 2015; 47(2):98-104.

Gill JS, Arora S, Khanna SP and Kumar H. Prevalence of Multidrug-resistant, Extensively Drug-resistant, and Pandrug-resistant Pseudomonas aeruginosa from a Tertiary Level Intensive Care Unit. J Glob Infect Dis. 2016 Oct-Dec; 8(4): 155–159.

Walkty A, Lagace-Wiens P, Adam H, Baxter M, James Karlowsky J, Mulvey M, McCracken M, Zhanel G. Antimicrobial susceptibility of 2906 Pseudomonas aeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8years: Results of the Canadian Ward surveillance study(CANWARD), 2008–2015. Diagnostic Microbiology and Infectious Disease. 2017;87: 60–63.

Sader HS, Huband MD, Castanheira M, Flamm RK. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. Antimicrobial Agents and ChemotherapyMarch 2017; 61 (3):1-7.

Sonnet P, Izard D, Mullié C. Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-_-naphthylamide. International Journal of Antimicrobial Agents. 2012; 39: 77– 80.

Ranji N, Rahbar Takrami S. Role of Mexz Gene in Ciprofloxacin Resistance in Pseudomonas aeruginosa isolate in Guilan Province.The Journal of Urmia University of Medical Sciences. 2017; 26(10), 902-912.

Negi N, Prakash P, Gupta ML, Mohapatra TM. Possible Role of Curcumin as an Efflux Pump Inhibitor in Multi Drug Resistant Clinical Isolates of Pseudomonas aeruginosa. Journal of Clinical and Diagnostic Research. 2014 Oct, Vol-8(10): 4-7.

Shawar R, Macleod D, Garber R, Burns J, Stapp JR, Clausen C, Tanaka SK. Activities of Tobramycin and Six Other Antibiotics againstPseudomonas aeruginosa Isolates from Patientswith Cystic Fibrosis. Antimicrobial Agents and Chemotherapy. Dec. 1999; 43(12): 2877–2880.

Bouza E, Garcia-Garrote F, Cercenado E, Marin M, Diaz MS. Pseudomonas aeruginosa: a Survey of Resistance in 136 Hospitals in Spain. Antimicrobial Agents and Chemotherapy, Apr. 1999;43(4) 981–982.

Eldere J V. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. Journal of Antimicrobial Chemotherapy. 2003; 51: 347–352.

Fernando DM, Kumar A. Resistance-nodulation-division multidrug efflux pumps in gram-negative bacteria: role in virulence. Antibiotics. 2013; 2(1):163-81.

Ardebili A, Talebi M, Azimi L, Lari AR. Effect of efflux pump inhibitor Carbonyl Cyanide 3-Chlorophenylhydrazone on the minimum inhibitory concentration of ciprofloxacin in Acinetobacter baumannii clinical isolates. Jundishapur Journal of Microbiology. 2014; 7(1).e8691.

Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrobial agents and chemotherapy. 2001; 45(1):105-16.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.